Abstract
Osteosarcoma (OS) is an aggressive mesenchymal tumor for which no molecularly targeted therapies are available. We have previously identified TRAF2- and NCK-interacting protein kinase (TNIK) as an essential factor for the transactivation of Wnt signal target genes and shown that its inhibition leads to eradication of colorectal cancer stem cells. The involvement of Wnt signaling in the pathogenesis of OS has been implicated. The aim of the present study was to examine the potential of TNIK as a therapeutic target in OS. RNA interference or pharmacological inhibition of TNIK suppressed the proliferation of OS cells. Transcriptome analysis suggested that a small-molecule inhibitor of TNIK upregulated the expression of genes involved in OS cell metabolism and downregulated transcription factors essential for maintaining the stem cell phenotype. Metabolome analysis revealed that this TNIK inhibitor redirected the metabolic network from carbon flux toward lipid accumulation in OS cells. Using in vitro and in vivo OS models, we confirmed that TNIK inhibition abrogated the OS stem cell phenotype, simultaneously driving conversion of OS cells to adipocyte-like cells through induction of PPARγ. In relation to potential therapeutic targeting in clinical practice, TNIK was confirmed to be in an active state in OS cell lines and clinical specimens. From these findings, we conclude that TNIK is applicable as a potential target for treatment of OS, affecting cell fate determination.
Highlights
Osteosarcoma (OS) is a rare malignant bone tumor that mainly affects adolescents and young adults
We investigated the potential of TRAF2- and NCKinteracting protein kinase (TNIK)-targeted treatment for OS, revealing that TNIK is required for OS cell proliferation and stemness and that its inhibition leads to conversion of OS cells to adipocytes
To ensure that the antiproliferative effects of siRNA constructs targeting TNIK transfection in OS cell lines were due to selective depletion of TNIK, we used 2 additional siRNA constructs that targeted different regions of TNIK mRNA
Summary
Osteosarcoma (OS) is a rare malignant bone tumor that mainly affects adolescents and young adults. It has been reported that inhibition of Wnt signaling converts the fate of mesenchymal precursors from osteoblasts to adipocytes through switching of lineage-specific transcription factors [11, 14]. This cell lineage conversion might be applicable to the treatment of OS. TNIK is essential for the transactivation of Wnt signal target genes, and its expression is associated with poor prognosis in patients with hepatocellular [17], colorectal [18], and pancreatic [19] cancers. We investigated the potential of TNIK-targeted treatment for OS, revealing that TNIK is required for OS cell proliferation and stemness and that its inhibition leads to conversion of OS cells to adipocytes
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
